多功能基诺林衍生开启光探针用于阿尔茨海默病的检测和治疗
Priyam Ghosh1, Sayantani Mukhopadhyay2, Thirukumaran Kandasamy3
1Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati 781039, Assam, India. pki@iitg.ac.in.
Journal of materials chemistry. B
|December 16, 2024
概括
一种新型分子M8HQ有效向粉样β (Aβ) 纤维素,显示出阿尔茨海默病 (AD) 诊断和治疗的前景. 它分解纤维,保护细胞免受氧化应激,并合金属离子,为AD治疗提供了多方面的方法.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生化学
- 分子生物学分子生物学
背景情况:
- 异常的蛋白质聚合,特别是粉样β (Aβ) 纤维化,是神经退行性疾病的核心,如阿尔茨海默病 (AD).
- 开发有效的AD诊断和治疗策略需要了解抑制粉样蛋白形成的分子相互作用.
研究的目的:
- 开发和描述M8HQ,一种新型的8-基诺林衍生小分子探针,作为阿尔茨海默病的潜在诊断和治疗剂.
- 研究M8HQ与Aβ纤维相互作用的能力,调节细胞过程,并提供神经保护.
主要方法:
- 合成和M8HQ分子的表征.
- 在体外试验测试以评估Aβ纤维结合,分离和抑制纤维化.
- 细胞研究以评估溶酶体向,LAMP1表达和反应性氧物种 (ROS) 介导的亡.
- 金属离子化试验.
- 分子对接和模拟研究以阐明与Aβ的结合相互作用.
主要成果:
- M8HQ表现出对Aβ纤维的强烈亲和力和有效的分解能力.
- 证实了M8HQ的溶解体局部化,有助于恢复细胞平衡和LAMP1表达.
- M8HQ抑制了ROS介导的亡,表现出神经保护作用.
- 该分子有效化Cu (II) 和Fe (III) 离子,减轻金属诱导的聚合.
- 分子建模证实了M8HQ和Aβ之间的稳定结合相互作用.
结论:
- M8HQ表现出多方面的特性,包括Aβ纤维素向,分解,溶酶体定位,神经保护和金属离子化.
- 这些综合特征使M8HQ成为阿尔茨海默病综合诊断和治疗应用的有希望的候选者.
- 对M8HQ的进一步研究可能会导致针对AD进展的新策略.
相关概念视频
Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444


